

## PROVINCIAL FUNDING SUMMARY

### Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: February 11, 2015

This information is current as of July 9, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	May 1, 2016	<p>Patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma</p> <p>Patients not candidates for fludarabine-based therapy due to co-morbidities or renal insufficiency</p> <p>Patients with symptomatic disease requiring systemic treatment</p> <p>NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment (please refer to <a href="https://cap.phsa.ca/">https://cap.phsa.ca/</a>).</p>
AB	Funded	Aug 6, 2015	<p>In combination with chlorambucil in patients with previously untreated CLL and adequate renal function for whom fludarabine-based treatment is considered inappropriate. Not to be used after progression on 1st line ibrutinib.</p>
SK	Funded	Jun 22, 2015	<p>In combination with Chlorambucil for patients with CLL/SLL who have adequate renal function and for whom fludarabine-based treatment is considered inappropriate and who either are previously untreated or who have received prior anti-CD20 therapy with a treatment free interval of greater than 3 years since the last dose of anti-CD20 therapy.</p>

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
MB	Funded	Jun 22, 2015	For first line treatment in combination with chlorambucil for patients with chronic lymphocytic leukemia and are ineligible to receive fludarabine. Patients who have initiated single-agent chlorambucil as first line therapy within the past 3 months are eligible to receive obinutuzumab in combination with chlorambucil. Obinutuzumab in combination with chlorambucil for patients with previously treated chronic lymphocytic leukemia with single-agent chlorambucil and who have been disease free for 2 years or more and have not received prior CD20 antibody therapy and who are considered fludarabine-ineligible.
ON	Funded	July 17, 2015	<p>Eligibility Criteria:</p> <ul style="list-style-type: none"> <li>a) Patient has previously untreated chronic lymphocytic leukemia (CLL)</li> <li>b) Patient has adequate renal function</li> <li>c) Fludarabine-based treatment is considered inappropriate for this patient</li> <li>d) Obinutuzumab will be used in combination with chlorambucil</li> </ul> <p>Funded Dose:</p> <ul style="list-style-type: none"> <li>-Cycle 1: 100 mg intravenously on day 1, 900 mg intravenously on day 2, 1000 mg intravenously on days 8 and 15</li> <li>-Cycles 2 to 6: 1000 mg intravenously on day 1 only</li> <li>-Cycles are 28 days</li> <li>-Obinutuzumab will be used in combination with chlorambucil</li> </ul> <p>Notes:</p> <ul style="list-style-type: none"> <li>-On a time limited basis (6 months), patients who initiated chlorambucil for previously untreated CLL in the three months prior to July 17, 2015 and whose disease has not progressed will have the option of adding obinutuzumab.</li> <li>-To be eligible for funding, patients must be able to start obinutuzumab in combination with chlorambucil. During the course of treatment, chlorambucil may be temporarily held due to toxicity or intolerance.</li> <li>-Screening for Hepatitis B virus with HBsAg and HBcAb has been completed or is in progress</li> </ul>

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
NS	Funded	Oct 15, 2015	In combination with chlorambucil for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have adequate renal function for whom fludarabine based treatment is considered inappropriate. Patients who have initiated single agent chlorambucil as first line therapy (fludarabine ineligible) within the past 3 months are eligible to receive obinutuzumab in combination with chlorambucil. Obinutuzumab in combination with chlorambucil may be considered as an option for CLL/SLL patients previously treated with single agent chlorambucil and have been disease free for 2 years or more and have not received prior CD20 antibody therapy and are considered fludarabine ineligible.
NB	Funded	May 2, 2016	In combination with chlorambucil for patients with previously untreated chronic lymphocytic leukemia (CLL) who have adequate renal function and for whom fludarabine-based treatment is considered inappropriate. Patients who have initiated single agent chlorambucil as first line therapy within the three months prior to May 1, 2016 are eligible to receive obinutuzumab in combination with chlorambucil.
NL	Funded	July 3, 2018	<ul style="list-style-type: none"> <li>- In combination with chlorambucil for previously untreated chronic lymphocytic leukemia (CLL) and adequate renal function, for whom fludarabine based treatment is considered inappropriate</li> <li>- In combination with chlorambucil for previous untreated chronic lymphocytic leukemia (CLL) where fludarabine based therapy is considered inappropriate and the patient has initiated treatment with single agent chlorambucil in the past 3 months OR</li> <li>- In combination with chlorambucil for previously treated chronic lymphocytic leukemia (CLL) with single agent chlorambucil and who have been disease free for 2 years or more and have not received prior CD20 antibody therapy and who are considered fludarabine ineligible.</li> </ul>
PEI	Under provincial consideration		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.